Pharmacokinetics and Pharmacodynamics — MCQs

A clinical pharmacologist is gathering pharmacokinetic data during clinical trials of a new antimicrobial agent. He has already determined that the half-life of this drug is 4 hours. He began a continuous intravenous drip 24 hours ago at a rate of 10 mg/min. Blood tests after 24 hours reveal that the patient's drug plasma concentration is 20 mg/L. What is the clearance of this agent?

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 41: In competitive antagonism, what happens to the Vmax?

A. Vmax remains the same (Correct Answer)
B. Potency remains the same
C. Km decreases
D. Efficacy decreases

Explanation: In **competitive antagonism**, the antagonist binds reversibly to the same active site as the agonist. Because they compete for the same receptor, the outcome depends on the relative concentrations of the two molecules. ### Why the correct answer is right: * **Vmax (Efficacy) remains the same:** If you increase the concentration of the agonist sufficiently, it can "outcompete" and displace the antagonist from the receptors. Therefore, the maximal response (Vmax or Emax) can still be achieved, provided enough agonist is present. On a graph, this is represented by a **parallel rightward shift** of the dose-response curve. ### Why the incorrect options are wrong: * **Potency remains the same:** This is incorrect. Because more agonist is required to achieve the same effect in the presence of an antagonist, the **EC50 increases**, meaning the **potency decreases**. * **Km decreases:** In enzyme kinetics (analogous to receptor binding), competitive inhibition **increases the Km** (Michaelis constant). A higher Km indicates a decreased affinity of the enzyme/receptor for the substrate/agonist. * **Efficacy decreases:** This is a characteristic of **non-competitive antagonism**, where the antagonist binds to an allosteric site or binds irreversibly, preventing the agonist from reaching Vmax regardless of the dose. ### High-Yield Clinical Pearls for NEET-PG: * **Competitive Antagonism:** Parallel rightward shift, Vmax constant, Km/EC50 increases. (Example: Atropine vs. Acetylcholine). * **Non-Competitive Antagonism:** Downward shift, Vmax decreases, Km/EC50 remains constant. (Example: Phenoxybenzamine at alpha receptors). * **Key Distinction:** Competitive antagonism can be overcome by increasing agonist concentration; non-competitive cannot.

Question 42: Which route of administration will produce the least onset of action?

A. Application to a serous surface
B. Inhalation of gaseous form
C. Application to a bronchotracheal mucous membrane (Correct Answer)
D. Injection into blood vessels

Explanation: ### Explanation The speed of onset of action for any drug is primarily determined by the **vascularity** of the site of administration and the **surface area** available for absorption. **Why Option C is Correct:** The **bronchotracheal mucous membrane** has a relatively smaller surface area and lower vascular density compared to the alveolar surface or direct intravenous access. While absorption through mucous membranes is generally faster than the oral route, it is significantly slower than the other options provided. Therefore, among the choices, it produces the **least (slowest) onset of action.** **Analysis of Incorrect Options:** * **D. Injection into blood vessels (Intravenous):** This provides the **fastest** onset of action because it bypasses the absorption phase entirely, achieving immediate 100% bioavailability. * **B. Inhalation of gaseous form:** This involves the **alveolar membrane**, which has a massive surface area (approx. 70-100 $m^2$) and an extremely rich capillary network. This results in an onset of action almost as rapid as an IV injection (e.g., volatile anesthetics). * **A. Application to a serous surface:** Serous membranes (like the peritoneum) have a very large surface area and high vascularity, leading to very rapid absorption, often faster than mucous membrane application. **NEET-PG High-Yield Pearls:** * **Order of Onset Speed:** IV > Inhalation (Alveolar) > Intraperitoneal/Serous > Intramuscular > Subcutaneous > Oral. * **Bioavailability:** Defined as the fraction of an unchanged drug that reaches the systemic circulation. It is 100% (1.0) for the IV route. * **First-Pass Metabolism:** Routes that bypass the liver (IV, Sublingual, Transdermal, Inhalation) have higher systemic availability compared to the oral route.

Question 43: Which of the following drugs exhibit zero-order kinetics at high doses?

A. Phenytoin and Propranolol (Correct Answer)
B. Digoxin and Propranolol
C. Amiloride and Probenecid
D. Lithium and Theophylline

Explanation: ### Explanation **Concept: Zero-Order vs. First-Order Kinetics** Most drugs follow **First-Order Kinetics**, where a constant *fraction* of the drug is eliminated per unit time (rate depends on plasma concentration). However, some drugs exhibit **Zero-Order Kinetics** (Non-linear/Saturation kinetics), where a constant *amount* of the drug is eliminated per unit time because the metabolic enzymes or transporters become saturated. **Why Option A is Correct:** * **Phenytoin:** It is the classic example of saturation kinetics. At low doses, it follows first-order kinetics, but as the metabolic enzymes (CYP2C9) saturate at therapeutic levels, it shifts to zero-order. Small dose increases can lead to disproportionately large increases in plasma levels and toxicity. * **Propranolol:** While primarily first-order, it exhibits saturable first-pass metabolism at high doses, leading to zero-order characteristics. **Analysis of Incorrect Options:** * **Option B (Digoxin):** Digoxin follows first-order kinetics. Its narrow therapeutic index requires monitoring, but its elimination rate remains proportional to its concentration. * **Option C (Amiloride and Probenecid):** Both are eliminated via first-order kinetics. Probenecid is a competitive inhibitor of renal tubular secretion but does not typically exhibit zero-order elimination. * **Option D (Lithium and Theophylline):** Lithium follows strict first-order kinetics. Theophylline follows first-order kinetics at therapeutic ranges, though it can show saturation kinetics in cases of severe toxicity (overdose). **High-Yield Clinical Pearls for NEET-PG:** To remember the drugs following **Zero-Order Kinetics**, use the mnemonic **"WATT PA"**: * **W**arfarin (at very high doses) * **A**lcohol (Ethanol) - *Most common example* * **T**heophylline (at high doses/toxic levels) * **T**olbutamide * **P**henytoin / **P**henylbutazone * **A**spirin (Salicylates) **Key Distinction:** In zero-order kinetics, the **half-life ($t_{1/2}$) is not constant**; it increases as the plasma concentration increases.

Question 44: Drug excretion through the kidney depends on all EXCEPT:

A. High blood flow in the kidney
B. Molecular weight of the drug (Correct Answer)
C. Lipid solubility of the drug
D. Plasma protein binding of the drug

Explanation: **Explanation:** Drug excretion by the kidney is a complex process involving glomerular filtration, active tubular secretion, and passive tubular reabsorption. **Why Molecular Weight is the Correct Answer (The Exception):** In the context of renal excretion, **molecular weight (MW)** is generally not a limiting factor for most drugs. The glomerular capillary wall has large pores (fenestrae) that allow the filtration of molecules up to approximately 60,000 Daltons (the size of albumin). Since most drugs have a MW between 100 and 1,000 Daltons, they are filtered freely regardless of their specific size. Therefore, variations in MW among standard drugs do not significantly influence their renal excretion rate. **Analysis of Other Options:** * **High Blood Flow (A):** Glomerular filtration rate (GFR) is directly proportional to renal blood flow. If blood flow decreases (e.g., in shock or heart failure), the delivery of the drug to the nephron decreases, reducing excretion. * **Lipid Solubility (C):** This is a critical factor in **tubular reabsorption**. Highly lipid-soluble drugs are easily reabsorbed from the renal tubules back into the systemic circulation, decreasing their net excretion. Conversely, water-soluble (polar) drugs remain in the tubule and are excreted. * **Plasma Protein Binding (D):** Only the **free (unbound) fraction** of a drug can be filtered at the glomerulus. Drugs highly bound to plasma proteins (like albumin) are not filtered, which significantly slows their renal clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Ion Trapping:** To increase the excretion of acidic drugs (e.g., Aspirin, Phenobarbitone), we **alkalinize the urine** with Sodium Bicarbonate. This ionizes the drug, making it lipid-insoluble and preventing reabsorption. * **Active Secretion:** Some drugs (e.g., Penicillin) are actively secreted in the proximal tubule. This process is saturable and can be inhibited by **Probenecid**, which is used clinically to prolong the half-life of Penicillin. * **Formula:** Renal Clearance ($CL_r$) = (Rate of filtration + Rate of secretion) – Rate of reabsorption.

Question 45: Which of the following drugs is not converted into an active metabolite?

A. Cyclophosphamide
B. Diazepam
C. Fluoxetine
D. Lisinopril (Correct Answer)

Explanation: **Explanation:** The question tests the concept of **Prodrugs** and **Active Metabolites**. Most drugs are inactivated by metabolism, but some are converted into active forms to exert their therapeutic effects. **Why Lisinopril is the Correct Answer:** Lisinopril is a notable exception among ACE inhibitors. While most ACE inhibitors (like Enalapril, Ramipril, and Perindopril) are **prodrugs** that must be converted by the liver into their active "-at" forms (e.g., Enalaprilat), **Lisinopril and Captopril are already active drugs**. They do not undergo hepatic activation and are excreted unchanged by the kidneys. This makes Lisinopril a preferred choice in patients with hepatic impairment. **Analysis of Incorrect Options:** * **Cyclophosphamide:** This is a classic **prodrug**. It is inactive in vitro and must be activated by hepatic cytochrome P450 enzymes into **4-hydroxycyclophosphamide** and **aldophosphamide** to exert its cytotoxic effect. * **Diazepam:** This benzodiazepine has a very long half-life because it is converted into several **active metabolites**, including **nordiazepam** (desmethyldiazepam) and **oxazepam**, which prolong its sedative effects. * **Fluoxetine:** This SSRI is metabolized into **norfluoxetine**, an active metabolite with an even longer half-life (7–15 days) than the parent drug, contributing to its sustained clinical effect. **NEET-PG High-Yield Pearls:** * **ACE Inhibitor Rule:** All ACE inhibitors are prodrugs **EXCEPT** Captopril and Lisinopril. * **Active Metabolite of Morphine:** Morphine-6-glucuronide (more potent than morphine). * **Prodrug of Epinephrine:** Dipivefrine (used in glaucoma). * **Prodrug of Dopamine:** Levodopa (crosses the blood-brain barrier).

Question 46: What is Hoffmann's elimination?

A. Inactivation of a drug by a metabolizing enzyme.
B. Unchanged excretion of a drug by the kidney.
C. Excretion of a drug in the feces.
D. Inactivation of a drug by molecular rearrangement. (Correct Answer)

Explanation: ### **Explanation** **Hoffmann's elimination** is a unique pharmacokinetic process where a drug undergoes spontaneous non-enzymatic degradation in the plasma and tissues. **1. Why Option D is Correct:** The correct answer is **inactivation of a drug by molecular rearrangement**. Unlike most drugs that require hepatic enzymes or renal clearance, drugs undergoing Hoffmann's elimination break down spontaneously due to the physiological pH and temperature of the body. This is a purely chemical process (molecular rearrangement) that does not involve any biological catalysts (enzymes). **2. Why Other Options are Incorrect:** * **Option A:** This refers to **biotransformation** (metabolism), typically occurring in the liver via Cytochrome P450 enzymes. * **Option B:** This refers to **renal excretion**, the primary route for water-soluble drugs. * **Option C:** This refers to **biliary or fecal excretion**, common for large molecular weight compounds or unabsorbed oral drugs. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Prototype Drug:** The classic example is **Atracurium** (a non-depolarizing neuromuscular blocker). Its derivative, **Cisatracurium**, also undergoes this process. * **Clinical Advantage:** Because it does not rely on the liver or kidneys, Atracurium is the **muscle relaxant of choice for patients with liver or kidney failure**. * **Factors Affecting Rate:** Since it is a chemical reaction, the rate of Hoffmann's elimination is increased by **hyperthermia** and **alkalosis**, and decreased by hypothermia and acidosis. * **Metabolite Note:** A byproduct of this reaction is **laudanosine**, which can cross the blood-brain barrier and potentially cause seizures in very high concentrations (though rare clinically).

Question 47: Which of the following pairs of drugs are metabolized by the same Cytochrome enzyme?

A. Omeprazole and Clopidogrel (Correct Answer)
B. Phenytoin and Tacrolimus
C. Paracetamol and Warfarin
D. Omeprazole and Warfarin

Explanation: **Explanation:** The correct answer is **A. Omeprazole and Clopidogrel**. Both drugs are primary substrates for the isoenzyme **CYP2C19**. **1. Why Option A is Correct:** Clopidogrel is a prodrug that requires activation by the CYP2C19 enzyme to its active thiol metabolite to exert its antiplatelet effect. Omeprazole is also metabolized by (and is a potent inhibitor of) CYP2C19. This shared pathway is clinically significant because omeprazole can competitively inhibit the activation of clopidogrel, potentially leading to reduced antiplatelet efficacy and an increased risk of cardiovascular events. **2. Analysis of Incorrect Options:** * **B. Phenytoin and Tacrolimus:** Phenytoin is primarily metabolized by **CYP2C9** (and 2C19), whereas Tacrolimus is a major substrate of **CYP3A4**. * **C. Paracetamol and Warfarin:** Paracetamol is mainly metabolized via glucuronidation and sulfation (with a small portion via **CYP2E1** to NAPQI), while Warfarin (specifically the more potent S-isomer) is metabolized by **CYP2C9**. * **D. Omeprazole and Warfarin:** As noted, Omeprazole uses **CYP2C19**, while Warfarin uses **CYP2C9**. **High-Yield NEET-PG Pearls:** * **CYP3A4:** The most abundant CYP enzyme; metabolizes ~50% of all drugs (e.g., Statins, CCBs, HIV Protease inhibitors). * **CYP2D6:** Shows significant genetic polymorphism; metabolizes Codeine, Metoprolol, and Haloperidol. * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**rimethoprim, **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**il (Cimetidine), **K**etoconazole.

Question 48: Which statement about the absorption of acidic drugs is true?

A. Best absorbed in acidic medium (Correct Answer)
B. Best absorbed in alkaline medium
C. Not absorbed in acidic medium
D. Binds to alpha-1-acid glycoprotein

Explanation: **Explanation:** The absorption of drugs across biological membranes is primarily governed by the **pH Partition Hypothesis**. Most drugs are weak electrolytes, and their movement across lipid membranes depends on their degree of ionization. **1. Why Option A is Correct:** According to the Henderson-Hasselbalch equation, an **acidic drug** (like Aspirin or Barbiturates) remains in its **unionized (lipid-soluble) form** when placed in an **acidic medium** (low pH). Since only the unionized form can easily diffuse across the lipid bilayer of cell membranes, acidic drugs are best absorbed from the stomach or the proximal part of the duodenum where the pH is low. **2. Why Other Options are Incorrect:** * **Option B & C:** In an alkaline medium, acidic drugs become ionized (water-soluble). Ionized drugs are polar and cannot easily cross lipid membranes, leading to poor absorption. This principle is clinically utilized in "Urinary Alkalinization" to trap acidic drugs in the urine for excretion during toxicity. * **Option D:** Acidic drugs typically bind to **Plasma Albumin**. It is **basic drugs** (like Propranolol, Lidocaine, or Quinidine) that primarily bind to **Alpha-1-acid glycoprotein (AAG)**. **High-Yield NEET-PG Pearls:** * **Ion Trapping:** To treat acidic drug poisoning (e.g., Aspirin), we alkalinize the urine with Sodium Bicarbonate. This ionizes the drug in the renal tubules, preventing reabsorption and enhancing excretion. * **Binding Sites:** * **Acidic Drugs:** Bind to Albumin (Site I: Warfarin/Azapropazone; Site II: Diazepam/Ibuprofen). * **Basic Drugs:** Bind to Alpha-1-acid glycoprotein. * **Rule of Thumb:** "Like is unionized in like" (Acidic in Acidic / Basic in Basic). Only the unionized form is pharmacologically active and absorbable.

Question 49: Which of the following statements is true regarding the intravenous route of drug administration?

A. It is useful in emergencies
B. Aseptic precautions are required
C. Bioavailability is 100%
D. Suspensions can be administered (Correct Answer)

Explanation: ### Explanation The intravenous (IV) route is a parenteral method of drug administration where the drug is injected directly into the systemic circulation. **Why the "Correct" Answer is Suspensions can be administered (Note on Question Context):** In standard pharmacology (e.g., Katzung or KD Tripathi), it is traditionally taught that **suspensions should NOT be given intravenously** because particulate matter can cause embolism. However, in recent medical exams, this question often highlights exceptions. Ultra-fine **nano-suspensions** or specific lipid emulsions (like Propofol) are now administered IV. If this option is marked correct in your specific mock/source, it refers to these specialized formulations. *Note: In most standard exams, this is actually a "False" statement.* **Analysis of Other Options:** * **A. Useful in emergencies:** This is a **True** statement. The IV route has the fastest onset of action, making it the route of choice for emergencies (e.g., status epilepticus, anaphylaxis). * **B. Aseptic precautions are required:** This is a **True** statement. Since the skin barrier is bypassed and the drug enters the bloodstream directly, strict asepsis is mandatory to prevent sepsis or thrombophlebitis. * **C. Bioavailability is 100%:** This is a **True** statement. By definition, IV administration bypasses first-pass metabolism and absorption barriers, resulting in a bioavailability ($F$) of 1.0 (100%). **Clinical Pearls for NEET-PG:** * **Bioavailability ($F$):** Defined as the fraction of an administered dose that reaches the systemic circulation in unchanged form. For IV, $F=100\%$. * **First-pass metabolism:** Drugs given IV bypass the liver initially, unlike the oral route. * **Oil-based solutions:** These are strictly contraindicated via the IV route as they cause pulmonary oil embolism; they are typically given Intramuscularly (IM). * **Large volumes:** The IV route is the only route suitable for administering large volumes of fluids (infusions).

Question 50: A clinical pharmacologist is gathering pharmacokinetic data during clinical trials of a new antimicrobial agent. He has already determined that the half-life of this drug is 4 hours. He began a continuous intravenous drip 24 hours ago at a rate of 10 mg/min. Blood tests after 24 hours reveal that the patient's drug plasma concentration is 20 mg/L. What is the clearance of this agent?

A. 0.5 L/min (Correct Answer)
B. 2 L/min
C. 10 L/min
D. 50 L/min

Explanation: The core concept required to solve this problem is the relationship between infusion rate, clearance, and steady-state concentration. [1] **1. Why Option A is Correct:** When a drug is administered via continuous intravenous infusion, it eventually reaches a **Steady State (Css)**, where the rate of drug administration (Input) equals the rate of drug elimination (Output). [1][3] * **Time to Steady State:** It takes approximately 4 to 5 half-lives to reach steady state. [2] Given the half-life ($t_{1/2}$) is 4 hours, steady state is reached in 16–20 hours. Since the drug has been infused for 24 hours, we can safely assume the patient is at steady state. * **The Formula:** At steady state, $ ext{Infusion Rate (R0)} = ext{Clearance (Cl)} imes ext{Steady State Concentration (Css)}$. [1] * **Calculation:** * $R0 = 10 ext{ mg/min}$ * $Css = 20 ext{ mg/L}$ * $Cl = R0 / Css = 10 ext{ mg/min} / 20 ext{ mg/L} = \mathbf{0.5 ext{ L/min}}$. [3] **2. Why Incorrect Options are Wrong:** * **Option B (2 L/min):** This results if you incorrectly divide $Css$ by $R0$ ($20/10$). * **Option C (10 L/min):** This assumes a 1:1 ratio, ignoring the concentration value. * **Option D (50 L/min):** This value is mathematically inconsistent with the provided steady-state parameters. **3. High-Yield Clinical Pearls for NEET-PG:** * **Steady State:** It is independent of the dose or infusion rate; it depends *only* on the half-life of the drug. [2] Increasing the infusion rate will increase the *level* of the steady state, but not the *time* taken to reach it. * **Loading Dose:** To reach steady state immediately, a loading dose ($LD = Vd \times Cp$) is required. * **Clearance:** It is the most important parameter in determining the **maintenance dose**. * **Rule of Thumb:** * 1 half-life = 50% of steady state * 2 half-lives = 75% * 3 half-lives = 87.5% * 4-5 half-lives = >95% (Clinically considered steady state). [2]

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free